# Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia

> **NCT02298075** · — · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 148 (actual)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** Romiplostin

## Key facts

- **NCT ID:** NCT02298075
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2019-04-17
- **Final completion:** 2019-04-17
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02298075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02298075, "Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02298075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*